Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03817307 | Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma(USPIO-NECK) | unknown | N/A | 25 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04803331 | SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification(MAG-NODE) | unknown | N/A | 10 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 |
| clinicaltrials |
| NCT02063399 | Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | unknown | — | 20,302 | Chinese University of Hong KongOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05024383 | Dissecting the Heterogeneity of Oral Cancer Pain | unknown | N/A | 80 | NYU College of DentistryOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05547971 | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics | unknown | — | 800 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05503914 | Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | unknown | N/A | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04214353 | PSMA-PET Imaging Before and After ADT in Advanced SDC Patients(ADT-SCAN) | unknown | N/A | 14 | Radboud University Medical CenterOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05499936 | 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC) | unknown | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05476965 | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma(iCSDeR) | unknown | Phase 2 | 20 | Hubei Cancer HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05037357 | Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements | unknown | — | 370 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05351762 | Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC | unknown | Phase 2 | 55 | Xijing HospitalOTHER | 0 | Jul 5, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05432219 | A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma | unknown | N/A | 20 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05417139 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05350891 | Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | unknown | Phase 2 | 77 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03854838 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04143984 | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 146 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02748707 | Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study(ERLO-XIB) | unknown | Phase 2 | 64 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04073784 | Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 1 | 41 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05341193 | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05341479 | An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma | unknown | — | 200 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04213404 | Ribociclib and Spartalizumab in R/M HNSCC(RISE-HN) | unknown | Phase 1 | 13 | National Taiwan University HospitalOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03346109 | To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma | unknown | N/A | 568 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04508829 | Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04921995 | Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma(RETICULA-NPC) | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05293327 | IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate(IMP3PCNA) | unknown | — | 70 | Sohag UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Institut Català d'OncologiaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05299203 | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | unknown | Phase 1 | 18 | West China HospitalOTHER | 0 | Mar 28, 2022 | clinicaltrials |
| NCT05291663 | Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck | unknown | — | 100 | Assiut UniversityOTHER | 0 | Mar 23, 2022 | clinicaltrials |
| NCT05289336 | DAHANCA 27 Transoral Laser Microsurgery for T1a Glottic Cancer(DAHANCA 27) | unknown | Phase 2 | 80 | Danish Head and Neck Cancer GroupNETWORK | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05075122 | Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab(FOCUS) | unknown | Phase 2 | 75 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03366415 | Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC | unknown | Phase 3 | 420 | Chaosu HuOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05267353 | Develop and Test the 'Multi-Faced Continuous Exercise Program' in Operable Head and Neck Cancer Patients | unknown | N/A | 390 | National Taiwan University HospitalOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05150509 | Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy(OSCC) | unknown | — | 110 | DR. MALA KHANOTHER_GOV | 1 | Feb 22, 2022 | clinicaltrials |
| NCT05247476 | Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. | unknown | Phase 4 | 50 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05232552 | Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05146050 | Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma | unknown | — | 107 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT05228093 | A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis | unknown | N/A | 216 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04740996 | Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | unknown | — | 30 | Shi YuankaiUNKNOWN | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05202275 | The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs | unknown | Phase 2 | 43 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05189184 | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma(HNSCC) | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jan 12, 2022 | clinicaltrials |
| NCT05183724 | Ovarian Function of Nasopharyngeal Carcinoma Women Survivors | unknown | — | 602 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 26, 2022source: clinicaltrials